(thirdQuint)AZD8108 SAD/MAD in Healthy Volunteers.

 In Part 1 of the study (single ascending dose portion), approximately 32 subjects will be randomly assigned.

 Eight (8) subjects will be randomized in each of 4 dosage-level cohorts (AZD8108 or placebo).

 Within each cohort, 6 subjects will be randomized to receive AZD8108 and 2 subjects will be randomized to receive placebo.

 Each subject will receive only one dose of either AZD8108 or placebo on Day 1.

 In Part 2 of the study (multiple ascending dose portion), approximately 24 subjects will be randomly assigned.

 Eight (8) subjects will be randomized in each of 3 dosage-level cohorts.

 Within each cohort, 6 subjects will be randomized to receive AZD8108 and 2 subjects will be randomized to receive placebo.

 Each subject will receive twelve doses of either AZD8108 or placebo.

 AZD8108 SAD/MAD in Healthy Volunteers@highlight

This is a randomized, double-blind, placebo-controlled study of single and multiple ascending dosage levels of AZD8108 in healthy volunteers.

 The study includes an up to 28-day screening period, an in-house period during which AZD8108 or placebo will be administered orally as a solution, and a 4- to 10-day follow-up period after discharge.

